As pharmaceutical manufacturers seek novel solutions for challenging conditions, cannabinoids—especially cannabidiol (CBD)—are emerging as promising candidates for drug innovation. With favorable regulatory developments and increasing scientific evidence supporting their potential in treating central nervous system disorders, pain, and cancer, cannabinoids are set to expand therapeutic possibilities. This whitepaper explores the latest research on cannabinoids and highlights how dsm-firmenich is partnering with the pharmaceutical industry to drive early-stage drug development in this exciting field. Download to learn more about advancing cannabinoid-based therapies.
Taste in pediatric drug formulations shapes acceptance and adherence. Here’s what formulators need to consider to support these vulnerable patients.
Discover how dsm-firmenich and ten23 health are transforming biologic formulation development through advanced excipient options.
Explore what newly published CBtru® pharmacokinetic data means for solid oral drug development—and why clinical evidence underpins meaningful innovation.
Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.
Don’t just take our word for it. Discover how our solutions can support your product development journey.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.